TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Oblique Therapeutics AB (publ)
Closing information (x1000 SEK)
| Closing information | 2024/12 | 2023/12 | 2022/12 (consolidated) |
| Turnover |
491
|
0
|
0 |
| Financial expenses |
65
|
60
|
2,034 |
| Earnings before taxes |
-29,347
|
-61,929
|
-53,547 |
| EBITDA |
-28,512
|
-37,765
|
-48,231 |
| Total assets |
17,143
|
18,561
|
18,176 |
| Current assets |
15,585
|
16,169
|
8,107 |
| Current liabilities |
5,084
|
6,122
|
11,261 |
| Equity capital |
11,209
|
11,589
|
3,363 |
| - share capital |
2,283
|
1,826
|
759 |
| Employees (average) |
10
|
18
|
18 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 (consolidated) |
| Solvency |
65.4%
|
62.4%
|
18.5% |
| Turnover per employee |
49
|
0
|
0 |
| Profit as a percentage of turnover | -5977.0% | ||
| Return on assets (ROA) |
-170.8%
|
-333.3%
|
-283.4% |
| Current ratio |
306.5%
|
264.1%
|
72.0% |
| Return on equity (ROE) |
-261.8%
|
-534.4%
|
-1592.2% |
| Change turnover |
491
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
-8
|
0
|
2 |
| Chg. No. of employees % | -44% | 13% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.